Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Proteogenomic Screens Identify Plasma Cell Specific Vulnerabilities to Halt Oncogenic Transcription in Multiple Myeloma

Arnold Bolomsky, Smriti Kanangat, Michele Ceribelli, Kristina Rinaldi, Lin Zhang, Elizabeth Hill, Jagan R. Muppidi, Craig J. Thomas, Ryan M. Young

Blood (2024) 144 (Supplement 1): 763.

https://doi.org/10.1182/blood-2024-208485

Published: 2024

Journal Articles

CTPS1 Is a Novel Therapeutic Target in Multiple Myeloma That Synergizes with Inhibition of ATR, CHEK1 or WEE1

Christina Pfeiffer, Alexander Michael Grandits, Hélène Asnagli, Anja Schneller, Julia Huber, Niklas Zojer, Martin Schreder, Andrew Parker, Arnold Bolomsky, Philip Beer, Heinz Ludwig

Blood (2022) 140 (Supplement 1): 7088–7089.

https://doi.org/10.1182/blood-2022-160333

Published: 2022

Journal Articles

Preclinical Validation Studies Support Causal Machine Learning Based Identification of Novel Drug Targets for High-Risk Multiple Myeloma

Arnold Bolomsky, Fred Gruber, PhD, Kathrin Stangelberger, MSc, Leon Furchtgott, PhD, Dominik Arnold, Puja Raut, Diane Wuest, PhD, Karl Runge, Iya Khalil, Niklas Zojer, MD, Nikhil Munshi, MD, Boris Hayete, PhD, Heinz Ludwig, MD

Blood (2018) 132 (Supplement 1): 3210.

https://doi.org/10.1182/blood-2018-99-117886

Published: 2018

Journal Articles

Single-cell exomes in an index case of amp1q21 multiple myeloma reveal more diverse mutanomes than the whole population

Dean Bryant, Will Tapper, Nicola J. Weston-Bell, Arnold Bolomsky, Li Song, Shengtao Xu, Andrew R. Collins, Niklas Zojer, Surinder Singh Sahota

Blood (2018) 132 (2): 232–235.

https://doi.org/10.1182/blood-2018-01-829291

Published: 2018

Includes: Supplemental data

Journal Articles

Maternal Embryonic Leucine Zipper Kinase Inhibitor OTSSP167 Inhibits Osteoclast Activity and Restores Osteoblast Activity in a Murine Model of Multiple Myeloma Bone Disease

Josephine Muller, Arnold Bolomsky, PhD, Kathrin Schonfelder, Frederic Baron, Yves Beguin, MD PhD, Heinz Ludwig, MD, Jo Caers, MD, Roy Heusschen, PhD

Blood (2017) 130 (Supplement 1): 4416.

https://doi.org/10.1182/blood.V130.Suppl_1.4416.4416

Published: 2017

Journal Articles

Multiple Myeloma Drivers of High Risk and Response to Stem Cell Transplantation Identified By Causal Machine Learning: Out-of-Cohort and Experimental Validation

Leon Furchtgott, PhD, Arnold Bolomsky, PhD, Fred Gruber, PhD, Mehmet Kemal Samur, PhD, Jonathan J. Keats, PhD, Jennifer Yesil, MS, Kathrin Stangelberger, MSc, Michel Attal, MD PhD, Philippe Moreau, MDPhD, Hervé Avet-Loiseau, MD PhD, Karl Runge, PhD, Diane Wuest, PhD, Kelly Rich, Iya Khalil, PhD, Boris Hayete, PhD, Heinz Ludwig, MD, Nikhil Munshi, MD, Daniel Auclair, PhD

Blood (2017) 130 (Supplement 1): 3029.

https://doi.org/10.1182/blood.V130.Suppl_1.3029.3029

Published: 2017

Journal Articles

Preclinical Evaluation of the First in Class BMI1 Inhibitor PTC-028 Confirms Potent Efficacy to Target BMI1-Addiction in Multiple Myeloma

Arnold Bolomsky, PhD, Roy Heusschen, PhD, Kathrin Stangelberger, MSc, Muller Joséphine, Marla Weetall, PhD, Art Branstrom, PhD, Niklas Zojer, MD, Jo Caers, MD, Heinz Ludwig, MD

Blood (2017) 130 (Supplement 1): 1804.

https://doi.org/10.1182/blood.V130.Suppl_1.1804.1804

Published: 2017

Journal Articles

Single Cell Whole Exome Sequencing in an Index Case of Amp1q21 Multiple Myeloma to Define Intraclonal Variation

Dean Bryant, PhD, Will Tapper, PhD, Nicola J Weston-Bell, PhD, Arnold Bolomsky, PhD, Li Song, PhD, Shengtao Xu, B.Sc, Andrew R Collins, PhD, Niklas Zojer, MD, Surinder Singh Sahota, PhD

Blood (2016) 128 (22): 5651.

https://doi.org/10.1182/blood.V128.22.5651.5651

Published: 2016

Journal Articles

Maternal Embryonic Leucine Zipper Kinase (MELK) Drives a High-Risk Gene Network and Represents an Attractive Novel Drug Target in Multiple Myeloma

Arnold Bolomsky, PhD, Roy Heusschen, PhD, Karin Schlangen, PhD, Kathrin Schönfelder, MSc, Joséphine Muller, MSc, Wolfgang Schreiner, PhD, Niklas Zojer, MD, Jo Caers, Heinz Ludwig, MD

Blood (2016) 128 (22): 309.

https://doi.org/10.1182/blood.V128.22.309.309

Published: 2016

Journal Articles

Maternal Embryonic Leucine Zipper Kinase (MELK): a Novel Marker of Poor Prognosis and Attractive Drug Target in High-Risk Patients with Multiple Myeloma

Arnold Bolomsky, Karin Schlangen, Artur Köhler, Goran Mitulovic, Wolfgang Schreiner, Niklas Zojer, MD, Heinz Ludwig

Blood (2015) 126 (23): 1823.

https://doi.org/10.1182/blood.V126.23.1823.1823

Published: 2015

Journal Articles

CXCR3 Binding Chemokines MIG, IP-10 and ITAC Are Predictors of Overall Survival in Newly Diagnosed Multiple Myeloma

Arnold Bolomsky, Niklas Zojer, MD, Martin Schreder, MD, Heinz Ludwig, Univ. Prof. Dr.

Blood (2014) 124 (21): 2052.

https://doi.org/10.1182/blood.V124.21.2052.2052

Published: 2014

Journal Articles

Vemurafenib Inhibits Myeloma Cell Growth Independent Of BRAF V600E Mutations, Potentiates The Activity Of Established Anti-Myeloma Drugs, but impairs Osteogenesis Via An HGF Autocrine Loop In Bone Marrow Stromal Cells

Arnold Bolomsky, Heinz Ludwig, MD, Niklas Zojer

Blood (2013) 122 (21): 5363.

https://doi.org/10.1182/blood.V122.21.5363.5363

Published: 2013

Journal Articles

Insulin Like Growth Factor Binding Protein 7 (IGFBP7) Is Downregulated in Multiple Myeloma with Consequneces for Myeloma Cell Growth and Bone Disease

Arnold Bolomsky, Dirk Hose, MD, Martin Schreder, MD, Anja Seckinger, MD, Tobias Meißner, Bernard Klein, Daniel Heintel, Sabine Pfeifer, Heinz Ludwig, Niklas Zojer

Blood (2012) 120 (21): 3947.

https://doi.org/10.1182/blood.V120.21.3947.3947

Published: 2012

Journal Articles

High Expression of the Thalidomide-Binding Protein Cereblon (CRBN) Is Associated with Improved Clinical Response in Patients with Multiple Myeloma Treated with Lenalidomide and Dexamethasone

Daniel Heintel, Arnold Bolomsky, Martin Schreder, MD, Sabine Pfeifer, Niklas Zojer, Ulrich Jäger, Heinz Ludwig, MD

Blood (2011) 118 (21): 2879.

https://doi.org/10.1182/blood.V118.21.2879.2879

Published: 2011

NARROW

Proteogenomic Screens Identify Plasma Cell Specific Vulnerabilities to Halt Oncogenic Transcription in Multiple Myeloma

CTPS1 Is a Novel Therapeutic Target in Multiple Myeloma That Synergizes with Inhibition of ATR, CHEK1 or WEE1

Preclinical Validation Studies Support Causal Machine Learning Based Identification of Novel Drug Targets for High-Risk Multiple Myeloma

Single-cell exomes in an index case of amp1q21 multiple myeloma reveal more diverse mutanomes than the whole population

Maternal Embryonic Leucine Zipper Kinase Inhibitor OTSSP167 Inhibits Osteoclast Activity and Restores Osteoblast Activity in a Murine Model of Multiple Myeloma Bone Disease

Multiple Myeloma Drivers of High Risk and Response to Stem Cell Transplantation Identified By Causal Machine Learning: Out-of-Cohort and Experimental Validation

Preclinical Evaluation of the First in Class BMI1 Inhibitor PTC-028 Confirms Potent Efficacy to Target BMI1-Addiction in Multiple Myeloma

Single Cell Whole Exome Sequencing in an Index Case of Amp1q21 Multiple Myeloma to Define Intraclonal Variation

Maternal Embryonic Leucine Zipper Kinase (MELK) Drives a High-Risk Gene Network and Represents an Attractive Novel Drug Target in Multiple Myeloma

Maternal Embryonic Leucine Zipper Kinase (MELK): a Novel Marker of Poor Prognosis and Attractive Drug Target in High-Risk Patients with Multiple Myeloma

CXCR3 Binding Chemokines MIG, IP-10 and ITAC Are Predictors of Overall Survival in Newly Diagnosed Multiple Myeloma

Vemurafenib Inhibits Myeloma Cell Growth Independent Of BRAF V600E Mutations, Potentiates The Activity Of Established Anti-Myeloma Drugs, but impairs Osteogenesis Via An HGF Autocrine Loop In Bone Marrow Stromal Cells

Insulin Like Growth Factor Binding Protein 7 (IGFBP7) Is Downregulated in Multiple Myeloma with Consequneces for Myeloma Cell Growth and Bone Disease

High Expression of the Thalidomide-Binding Protein Cereblon (CRBN) Is Associated with Improved Clinical Response in Patients with Multiple Myeloma Treated with Lenalidomide and Dexamethasone

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only